Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Tuesday

Zenas BioPharma (NASDAQ:ZBIO) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.85) per share and revenue of $10.00 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Zenas BioPharma Price Performance

NASDAQ ZBIO traded up $0.16 during midday trading on Tuesday, hitting $31.49. 42,408 shares of the company traded hands, compared to its average volume of 237,283. The company has a market cap of $1.33 billion, a PE ratio of -5.41 and a beta of -1.53. The company’s 50-day simple moving average is $22.39 and its 200-day simple moving average is $15.65. Zenas BioPharma has a 52 week low of $5.83 and a 52 week high of $34.33.

Insider Transactions at Zenas BioPharma

In other news, Director Jason Raleigh Nunn purchased 63,158 shares of the stock in a transaction on Thursday, October 9th. The stock was bought at an average price of $19.00 per share, with a total value of $1,200,002.00. Following the transaction, the director owned 1,173,395 shares in the company, valued at $22,294,505. The trade was a 5.69% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sr One Capital Management, Llc purchased 126,315 shares of the stock in a transaction on Thursday, October 9th. The shares were purchased at an average cost of $19.00 per share, with a total value of $2,399,985.00. Following the transaction, the insider owned 1,917,895 shares in the company, valued at $36,440,005. This trade represents a 7.05% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 923,035 shares of company stock worth $17,628,163. 16.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Zenas BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. acquired a new stake in Zenas BioPharma during the 2nd quarter worth about $118,000. Bank of America Corp DE lifted its position in Zenas BioPharma by 32.3% during the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after acquiring an additional 3,412 shares during the period. Rhumbline Advisers lifted its position in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after acquiring an additional 8,207 shares during the period. Finally, Geode Capital Management LLC lifted its position in Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after acquiring an additional 16,461 shares during the period.

Analyst Ratings Changes

Several analysts have issued reports on ZBIO shares. HC Wainwright increased their target price on Zenas BioPharma from $30.00 to $44.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zenas BioPharma in a research report on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and issued a $52.00 price objective on shares of Zenas BioPharma in a research report on Monday, October 27th. Morgan Stanley raised their price objective on Zenas BioPharma from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. Finally, Wedbush reissued an “outperform” rating and issued a $45.00 price objective (up previously from $40.00) on shares of Zenas BioPharma in a research report on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.33.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.